Lignocaine Market Research Report- Asia Pacific Forecast till 2027

Lignocaine/ Lidocaine Market Information: By Application (Local Anesthesia, Anti-Arrhythmic), By Formulation (Injectable, Topical, Inhalation), By End User (Hospitals & Clinics, Dentist, Academia and Research Institutes) - Asia Pacific Forecast till 2027

ID: MRFR/Pharma/3139-HCR | February 2021 | Region: Global | 85 pages

Please note that the assessment period of report has been updated from 2017-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Synopsis of Asia Pacific Lignocaine Market


Market Scenario


Lidocaine, also known as xylocaine or lignocaine, is a medication used in a spectrum of medical applications such as local anaesthetic, to treat ventricular tachycardia or arrhythmia, and to perform nerve blocks. Inhaled lidocaine is a cough suppressor that reduces cough reflex. Lidocaine’s mechanism of action is blocking sodium channels, thus preventing local neuron signal from reaching the brain. Lidocaine is an antiarrhythmic medication which reduces the contraction of heart.


Common side effects of lidocaine include sleepiness, muscle twitching, confusion, changes in vision, numbness, tingling sensation, vomiting, low blood pressure and an irregular heart rate. It is generally safe to use in pregnancy but patients with liver problems may require a smaller dose. Lidocaine is on the Asia Pacific Health Organization's List of Essential Medicines, and is inexpensive. Adverse effects of lidocaine are tremors, euphoria, hallucinations, bradycardia, arrhythmias, bronchospasm, dyspnea, etc.


The lidocaine sales are suffering from market fragmentation, which has put pressure on the price margins. The generics have captured the major market share and the rise of counterfeited products has also restricted the market growth. The other market constrains are low price and adverse side effects of lidocaine use. Market development strategy has been constrained as lidocaine has been around market for many decades. Thus there is presence of huge production capacity which has also put pressure on prices. This has led to large players quitting the market. However, product development in the form of formulation development has been successful as exemplified by inhalation sprays. Moreover the high volume and low value nature of lidocaine has restricted the market to small players.


However, the market is extremely stable and a player with efficient production will reflect stable revenues, the presence of large governmental contract market also needs to be tapped. Thus, production and distribution efficiency coupled with product development strategies is expected to be critical factors in the Asia Pacific lidocaine market.


The market is expected to witness extremely sluggish growth and is expected to reach USD 250 million by 2023, and the market is projected to grow at a CAGR of ~ 1.0 % during the forecast period 2017-2023.


Research Methodology Asia Pacific Lignocaine Market


Sources: Mayo Clinic, Healthline Media, MRFR Analysis


 


Intended Audience



  • Asia Pacific Lignocaine treatment manufacturers & suppliers

  • Research and development (R&D) companies

  • Hospitals and clinics

  • Academic institutes and universities


Figure 1          Asia Pacific Lignocaine Market by Applications, 2016 (%) Asia Pacific Lignocaine Market-

Segments


The Asia Pacific Lignocaine market has been segmented on the basis of application, formulation and end user.


Based on the application, the market has been segmented as local anesthesia, anti-arrhythmic and others.


Based on the formulation, the market has been segmented as injectable, topical, inhalation and others.


Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.


Regional Analysis


The Asia Pacific region accounts for a significant market share owing to large population and fast developing and expanding healthcare facilities. Additionally, the large unmet needs of populous countries such as China and India is resulting in greater growth of the Lignocaine market in the regions. The sluggish growth of the developed regions of world also has resulted in transfer of growth of the lignocaine market to the developing markets of Asia Pacific. The lidocaine market is expected to be led by countries such as China and India due to their large populations and large industrial base as compared to other Asia Pacific countries. However the nations of Vietnam, Cambodia, Myanmar, Indonesia etc. are witnessing faster growth as compared to other Asia Pacific countries.


The poorly developed countries are expected to be the fastest growing regions in the Asia Pacific. The larger unmet needs and the faster development of health facilities coupled with the cheaper and essential nature of the lidocaine is driving the market in these regions. The growing application of lidocaine for veterinary use is expected to drive the future market as these countries have large animal population.


Furthermore, concentration of the large low end and low tech companies in the developing countries of this region such as China and India is resulting in excess capacity which needs to be exploited. However the growth in this region can be constrained by the current political conditions, and poor healthcare development.


Key Players in the Asia Pacific Lignocaine Market


Some of the key players profiled in the report are Croma-Pharma GmbH, Cironpharma, Endo Pharmaceuticals, ESBA Laboratories, Sigma-Aldrich, Swati Spentose Pvt. Ltd., Sambria Pharmaceuticals, Pierrel S.p.A., Galen US Inc., Mahendra Chemicals, Iwaki Seiyaku Co., Ltd., Biotechnica Pharma Asia Pacific, Harman Finochem Limited, Endo International, and others.


 



Table of Content

1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Asia Pacific Lignocaine Market, by Application

6.1 Introduction

6.2 Local Anesthesia

6.2.1 Market Estimates & Forecast, 2020-2027

6.3 Anti-Arrhythmic

6.3.1 Market Estimates & Forecast, 2020-2027

6.4 Others

6.4.1 Market Estimates & Forecast, 2020-2027

7. Asia Pacific Lignocaine Market, by Formulation

7.1 Introduction

7.2 Injectable

7.2.1 Market Estimates & Forecast, 2020-2027

7.3 Topical

7.3.1 Market Estimates & Forecast, 2020-2027

7.4 Inhalation

7.4.1 Market Estimates & Forecast, 2020-2027

7.5 Other

7.5.1 Market Estimates & Forecast, 2020-2027

8. Asia Pacific Lignocaine Market, by End User

8.1 Introduction

8.2 Hospitals & Clinics

8.2.1 Market Estimates & Forecast, 2020-2027

8.3 Academic and Research Institutes

8.3.1 Market Estimates & Forecast, 2020-2027

8.4 Dentist

8.4.1 Market Estimates & Forecast, 2020-2027

8.5 Others

8.5.1 Market Estimates & Forecast, 2020-2027

9. Asia Pacific Lignocaine Market, by Region

9.1 Introduction

9.2 China

9.3 India

9.4 Japan

9.5 Australia

9.6 Republic of Korea

9.7 Rest of the Asia Pacific

10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

11 Company Profiles

11.1 Croma-Pharma GmbH

11.1.1 Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 Key Developments

11.2 Cironpharma

11.2.1 Overview

11.2.2 Product Overview

11.2.3 Financials

11.2.4 Key Developments

11.3 Endo Pharmaceuticals

11.3.1 Overview

11.3.2 Product Overview

11.3.3 Financials

11.3.4 Key Development

11.4 ESBA Laboratories

11.4.1 Overview

11.4.2 Product Overview

11.4.3 Financials

11.4.3 Key Development

11.5 Sigma-Aldrich

11.5.1 Overview

11.5.2 Product Overview

11.5.3 Financials

11.5.4 Key Development

11.6 Swati Spentose Pvt. Ltd.

11.6.1 Overview

11.6.2 Product Overview

11.6.3 Financials

11.6.4 Key Development

11.7 Galen US Inc.

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Development

11.8 Mahendra Chemicals

11.8.1 Overview

11.8.2 Product Overview

11.8.3 Financials

11.8.4 Key Development

11.9 Iwaki Seiyaku Co., Ltd.

11.9.1 Overview

11.9.2 Product Overview

11.9.3 Financials

11.9.4 Key Development

11.10 Others

11.10.1 Overview

11.10.2 Product Overview

11.10.3 Financials

11.10.4 Key Development

12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Lignocaine Industry

13 Appendix

List of Tables

TABLE 1 ASIA PACIFIC LIGNOCAINE MARKET, BY APPLICATIONS, 2020-2027 (USD MILLION)

TABLE 2 LOCAL ANESTHESIA FOR LIGNOCAINE MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 3 ANTI-ARRHYTHMIC FOR LIGNOCAINE MARKET, BY REGION 2020-2027 (USD

MILLION)

TABLE 4 OTHERS FOR LIGNOCAINE MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 5 ASIA PACIFIC LIGNOCAINE MARKET, BY FORMULATION, 2020-2027 (USD MILLION)

TABLE 6 INJECTABLE OTHER FOR LIGNOCAINE MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 7 TOPICAL FOR LIGNOCAINE MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 8 INHALATION FOR LIGNOCAINE MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 9 OTHERS FOR LIGNOCAINE MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 10 ASIA PACIFIC LIGNOCAINE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 11 CHINA LIGNOCAINE MARKET, BY COUNTRY 2020-2027 (USD MILLION)

TABLE 12 CHINA LIGNOCAINE MARKET, BY APPLICATIONS 2020-2027 (USD MILLION)

TABLE 13 CHINA LIGNOCAINE MARKET, BY FORMULATION 2020-2027 (USD MILLION)

TABLE 14 CHINA LIGNOCAINE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 15 CHINA LIGNOCAINE MARKET BY REGION 2020-2027 (USD MILLION

TABLE 16 INDIA LIGNOCAINE MARKET BY COUNTRY 2020-2027 (USD MILLION)

TABLE 17 INDIA LIGNOCAINE MARKET, BY APPLICATIONS 2020-2027 (USD MILLION)

TABLE 18 INDIA LIGNOCAINE MARKET, BY FORMULATION 2020-2027 (USD MILLION)

TABLE 19 INDIA LIGNOCAINE MARKET, BY TREATMENT 2020-2027 (USD MILLION)

TABLE 20 INDIA LIGNOCAINE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 21 INDIA LIGNOCAINE MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 22 ASIA PACIFIC LIGNOCAINE MARKET BY COUNTRY 2020-2027 (USD MILLION)

TABLE 23 ASIA PACIFIC LIGNOCAINE MARKET, BY APPLICATIONS 2020-2027 (USD MILLION)

TABLE 24 ASIA PACIFIC LIGNOCAINE MARKET, BY FORMULATION 2020-2027 (USD MILLION)

TABLE 25 ASIA PACIFIC LIGNOCAINE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 26 ASIA PACIFIC LIGNOCAINE MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 27 JAPAN LIGNOCAINE MARKET, BY REGION 2020-2027 (USD MILLION)

TABLE 28 JAPAN LIGNOCAINE MARKET BY COUNTRY 2020-2027 (USD MILLION)

TABLE 29 JAPAN LIGNOCAINE MARKET, BY APPLICATIONS 2020-2027 (USD MILLION)

TABLE 30 JAPAN LIGNOCAINE MARKET, BY FORMULATION 2020-2027 (USD MILLION)

TABLE 31 JAPAN LIGNOCAINE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 32 JAPAN LIGNOCAINE MARKET, BY REGION 2020-2027 (USD MILLION)


List of Figures

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET DYNAMICS FOR ASIA PACIFIC LIGNOCAINE MARKET

FIGURE 3 ASIA PACIFIC LIGNOCAINE MAKRET, BY SEGMENT, 2020

FIGURE 4 ASIA PACIFIC LIGNOCAINE MARKET, BY REGION

FIGURE 5 ASIA PACIFIC LIGNOCAINE MARKET SHARE, BY APPLICATIONS 2020

FIGURE 6 ASIA PACIFIC LIGNOCAINE MARKET SHARE, BY FORMULATION 2020

FIGURE 7 ASIA PACIFIC LIGNOCAINE MARKET SHARE, BY END USER, 2020

FIGURE 8 ASIA PACIFIC LIGNOCAINE MARKET SHARE, 2020

FIGURE 9 ASIA PACIFIC LIGNOCAINE MARKET SHARE, BY REGION, 2020

FIGURE 10 CHINA LIGNOCAINE MARKET SHARE, BY COUNTRY, 2020

FIGURE 11 INDIA LIGNOCAINE MARKET SHARE, BY COUNTRY, 2020

FIGURE 12 ASIA PACIFIC LIGNOCAINE MARKET SHARE, BY COUNTRY, 2020

FIGURE 13 JAPAN LIGNOCAINE MARKET, BY REGION, 2020

FIGURE 14 ASIA PACIFIC LIGNOCAINE MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 15 CROMA-PHARMA GMBH: KEY FINANCIALS

FIGURE 16 CROMA-PHARMA GMBH: SEGMENTAL REVENUE

FIGURE 17 CROMA-PHARMA GMBH: GEOGRAPHICAL REVENUE

FIGURE 18 CIRONPHARMA: KEY FINANCIALS

FIGURE 19 CIRONPHARMA: SEGMENTAL REVENUE

FIGURE 20 CIRONPHARMA: GEOGRAPHICAL REVENUE

FIGURE 21 ENDO PHARMACEUTICALS: KEY FINANCIALS

FIGURE 22 ENDO PHARMACEUTICALS: SEGMENTAL REVENUE

FIGURE 23 ENDO PHARMACEUTICALS: GEOGRAPHICAL REVENUE

FIGURE 24 SIGMA-ALDRICH: KEY FINANCIALS

FIGURE 25 SIGMA-ALDRICH: SEGMENTAL REVENUE

FIGURE 26 SIGMA-ALDRICH: GEOGRAPHICAL REVENUE

FIGURE 27 MAHENDRA CHEMICALS: FINANCIAL REVENUE

FIGURE 28 MAHENDRA CHEMICALS: SEGMENTAL REVENUE

FIGURE 29 MAHENDRA CHEMICALS: GEOGRPAHICAL REVENUE

FIGURE 30 GALEN US INC.: FINANCIAL REVENUE

FIGURE 31 GALEN US INC.: SEGMENTAL REVENUE

FIGURE 32 GALEN US INC.: GEOGRPAHICAL REVENUE